Antiviral oxime phosphoramide compounds
2 Assignments
0 Petitions
Accused Products
Abstract
Compounds of Formula I: I and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
-
Citations
26 Claims
-
1. A compound of structural Formula I:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from:
-
(a) —
C1-8alkyl, unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR8, —
SH, —
NR9R10, —
C3-6cycloalkyl or spiro-C3-6cycloalkyl,(b) —
CH2-phenyl, unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl,(c) —
C3-6cycloalkyl, unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl,(d) phenyl or naphthyl, each unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl,(e) —
CH2CH2OCH3, —
CH2CH2CH2OCH3, —
CH2CH2SCH3, —
CH2CH2CH2SCH3, —
CH2CH2NHCH3, —
CH2CH2CH2NHCH3,(f) pyridyl, unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl, or(g) piperidinyl, pyrrolidinyl, tetrahydrofuranyl, or tetrahydropyranyl, each unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3 alkyl.
-
-
3. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from:
-
(a) —
C1-6alkyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR8, —
SH, —
NR9R10, —
C3-6cycloalkyl or spiro-C3-6cycloalkyl,(b) —
CH2-phenyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl,(c) —
C3-6cycloalkyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl,(d) phenyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl, or(e) pyridyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl.
-
-
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
R1 and R2 are joined together with the carbon to which they are both attached to form; (a) —
C3-6cycloalkyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3 alkyl,(b) a 4 to 6-membered saturated monocyclic heterocyclic ring unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10, —
C1-3alkyl or —
CH2-phenyl, or
-
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 is —
- C1-4alkyl.
-
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R5 and R6 are each independently selected from —
- C1-4alkyl;
or R5 and R6 are joined together with the carbon to which they are both attached to form —
C3-6cycloalkyl or a 4 to 6-membered heterocyclic ring.
- C1-4alkyl;
-
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R7 is:
-
(a) —
C1-10alkyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR12, —
SH, —
NR13R14, —
C3-6cycloalkyl or spiro-C3-6cycloalkyl,(b) —
CH2-phenyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR15, —
SH, —
NR13R14 or —
C1-3alkyl, or(c) —
C3-6cycloalkyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR15, —
SH, —
NR13R14 or —
C1-3alkyl.
-
-
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein:
-
R1 and R2 are each independently selected from unsubstituted or substituted —
C1-6alkyl, unsubstituted or substituted —
CH2-phenyl, unsubstituted or substituted —
C3-6cycloalkyl, unsubstituted or substituted phenyl, or unsubstituted or substituted pyridyl;
orR1 and R2 are joined together with the carbon to which they are both attached to form (a) —
C3-6cycloalkyl unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10 or —
C1-3alkyl;(b) a 4 to 6-membered saturated monocyclic heterocyclic ring unsubstituted or substituted with one to three substituents independently selected from fluoro, chloro, bromo, —
OR11, —
SH, —
NR9R10, —
C1-3alkyl or —
CH2-phenyl;
or
-
-
9. The compound of claim 1 that is:
-
pentyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)-L-alaninate;pentyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((1,3-diphenylpropan-2-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((1,3-diphenylpropan-2-ylidene)amino)oxy)phosphoryl)-L-alaninate;hexyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylidene-amino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)amino)-2-methyl-propanoate;benzyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)-L-alaninate;benzyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)-L-alaninate;isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((dicyclopentylmethylene)amino)oxy)phosphoryl)-L-alaninate; isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((pentan-3-ylideneamino)oxy)phosphoryl)-L-alaninate; isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclohexylideneamino)oxy)phosphoryl)-L-alaninate; isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((tetrahydro-4H-pyran-4-ylidene)amino)oxy)phosphoryl)-L-alaninate; isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((dicyclopropylmethylene)amino)oxy)phosphoryl)-L-alaninate; isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((1-benzylpiperidin-4-ylidene)amino)oxy)phosphoryl)-L-alaninate; isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)-L-alaninate;isopropyl (((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((diphenylmethylene)amino)oxy)phosphoryl)-L-alaninate isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-cyclohexylethylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-cyclohexylethylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-(pyridin-4-yl)ethylidene)amino)oxy)phosphoryl)-L-alaninate and isopropyl;(((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-(pyridin-4-yl)ethylidene)amino)oxy)phosphoryl)-L-alaninate;pentyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)-L-alaninate;pentyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-phenylethylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-phenylethylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-2,3-dihydro-1H-inden-1-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-2,3-dihydro-1H-inden-1-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-3,4-dihydronaphthalen-1(2H)-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-3,4-dihydronaphthalen-1(2H)-ylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((R)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-cyclopentylethylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl (((S)—
(((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((((E)-1-cyclopentylethylidene)amino)oxy)phosphoryl)-L-alaninate;isopropyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;butyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;butyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;pentyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;pentyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;isobutyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoateisobutyl;isobutyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoateisobutyl;butyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;butyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;cyclohexyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;cyclohexyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;cyclobutyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;cyclobutyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;ethyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;ethyl 2-(((R)—
((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;propyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;propyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;or a pharmaceutically acceptable salt thereof.
-
-
10. A pharmaceutical composition comprising an effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
-
11. The pharmaceutical composition of claim 10 further comprising an effective amount of one or more additional HIV antiviral agent selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.
-
12. The pharmaceutical composition of claim 10 further comprising an effective amount of one or more additional HIV antiviral agent selected from:
-
13. A method for treatment of infection by HIV or for the treatment or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
-
14. The method of claim 13 further comprising administering to the subject an effective amount of one or more additional HIV antiviral agent selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.
-
15. The method of claim 13 further comprising an effective amount of one or more additional HIV antiviral agent selected from:
-
16. A pharmaceutical composition comprising an effective amount of the compound of claim 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
-
17. The pharmaceutical composition of claim 16 further comprising an effective amount of one or more additional HIV antiviral agent selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.
-
18. The pharmaceutical composition of claim 16 further comprising an effective amount of one or more additional HIV antiviral agent selected from:
-
19. A method for treatment of infection by HIV or for treatment or delay in the onset of AIDS in a subject in need thereof which comprises administering to the subject an effective amount of the compound of claim 9 or a pharmaceutically acceptable salt thereof.
-
20. The method of claim 19 further comprising administering to the subject an effective amount of one or more additional HIV antiviral agent selected from HIV protease inhibitors, HIV integrase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, nucleoside HIV reverse transcriptase inhibitors, HIV fusion inhibitors and HIV entry inhibitors.
-
21. The method of claim 19 further comprising an effective amount of one or more additional HIV antiviral agent selected from:
-
22. The compound of claim 1 that is:
-
hexyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((propan-2-ylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;or a pharmaceutically acceptable salt thereof.
-
-
23. The compound of claim 1 that is:
-
hexyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;hexyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;or a pharmaceutically acceptable salt thereof.
-
-
24. The compound of claim 1 that is:
-
isopropyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)((cyclopentylideneamino)oxy)phosphoryl)amino)-2-methylpropanoate;or a pharmaceutically acceptable salt thereof.
-
-
25. The compound of claim 1 that is:
-
isopropyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;isopropyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;or a pharmaceutically acceptable salt thereof.
-
-
26. The compound of claim 1 that is:
-
butyl 2-(((R)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;butyl 2-(((S)—
((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(((2,6-dimethylheptan-4-ylidene)amino)oxy)phosphoryl)amino)-2-methylpropanoate;or a pharmaceutically acceptable salt thereof.
-
-
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from:
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeMerck Sharp & Dohme LLC (Merck & Co., Inc.)
-
Original AssigneeMerck Sharp & Dohme Corporation (Merck & Co., Inc.)
-
InventorsFu, Wenlang, Guo, Zhiqiang, Qi, Ning, Raheem, Izzat T., Vachal, Petr, Wang, Ming, Schreier, John D.
-
Primary Examiner(s)Bernhardt, Emily A
-
Application NumberUS16/061,732Publication NumberTime in Patent Office1,044 DaysField of SearchUS Class CurrentCPC Class CodesA61K 31/675 having nitrogen as a ring h...A61K 45/06 Mixtures of active ingredie...A61P 31/18 for HIVC07F 9/65616 containing the ring system ...